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Background: Mesenchymal stem cells (MSCs) are attractive cell sources for tissue 
engineering application because of their ability to proliferate and differentiate into 
mesenchymal tissues. MSCs derived from human gingiva are readily accessible and 
highly proliferative with the ability to differentiate into an osteogenic lineage, making 
them ideal sources for tissue regeneration of craniofacial defects. While dexamethasone 
is a traditional inducer of osteogenic differentiation, studies have shown that its 
prolonged presence in culture medium may have toxic effects on osteoblasts. Many 
antioxidants play a vital role in promoting osteogenic differentiation and offer a potential 
alternative to dexamethasone. It has been demonstrated that curcumin can promote 
osteogenesis of rat derived bone marrow mesenchymal cells, suggesting that curcumin 
can be used in the treatment of bone lesions. Previous studies reported that bromelain 
treatment relieved osteoarthritis, indicating that bromelain may be able to promote bone 
health, which gives a cue that bromelain can induce osteogenic differentiation in MSCs. 
Objective: The aim of this study was to investigate the effects of curcumin and 
	 viii	
bromelain on osteogenic differentiation of human gingiva derived mesenchymal stem 
cells (HGMSCs) and to compare their differentiation potential to dexamethasone. 
Methodology: Stem cells were isolated from human gingival tissue samples. Surface 
markers were detected using flow cytometry. Guided osteogenic differentiation assay was 
conducted to confirm mineralization. The effects of curcumin and bromelain on 
HGMSCs proliferation on day1, 3 and 5 was examined using a MTT assay. Cells were 
treated with various concentrations of curcumin (2, 5 and 10µM) and bromelain (1, 2.5 
and 5µg/ml) for two weeks and gene expression was investigated using quantitative PCR. 
Results: Our findings demonstrated that curcumin and bromelain induced osteogenic 
differentiation in a dose dependent manner. At 2.5µg/ml the peak up-regulation could be 
seen for genes Collagen, ALP, and OPG for bromelain treated cells. In curcumin the ideal 
concentration found was to 2µM. The maximum enhancement has been observed at 2µM 
for all genes. Conclusion: Cells treated with curcumin and bromelain induced the 
osteogenic differentiation, however, future in vivo studies need to be conducted to 
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CHAPTER 1. INTRODUCTION 
1.1 Craniofacial Birth Defects 
Craniofacial birth defects are among the most commonly occurring congenital anomalies 
found in newborns. Cleft lip with or without cleft palate is the most common 
craniofacial abnormality and the fourth most common congenital birth defect.1 Orofacial 
clefts are characterized by the deficiency and displacement of soft tissues and underlying 
cartilaginous and bony structures of the nasal sill, lip, and soft and hard palate.2 The cleft 
can vary in severity from a small notch in the vermillion border of the lip to a cleft that 
extends through the alveolar ridge of the maxilla to involve the floor of the nose or 
palate.  Clefts of the lip result when the medial and lateral nasal processes, the 
frontonasal prominence, and the maxillary prominence fail to unite. A unilateral cleft 
will result when the maxillary prominence on the affected side fails to merge with the 
nasal prominence. If the tissues fail to unite on both sides, a bilateral cleft lip will form. 
Cleft palate results with failure of the fusion of the palatal shelves with the nasal septum 
posteriorly.3,4 
 
1.2 Intramembranous Ossification 
During the eighth week of normal development, after fusion of the palatal shelves 
occurs, intramembranous ossification of the palate begins. Ossification will extend from 
the posterior part of the palate anteriorly, leaving the most posterior portion to become 
the region of the soft palate.5 During intramembranous ossification, neural crest derived 
mesencymal cells will proliferate and condense into compact nodules. Some of the  
mesencymal cells will differentiate into osteoblasts, bone precursor cells. These cells 
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will secrete osteoid, a collagen-proteoglycan matrix, that binds to calcium salts to 
become calcifed.  As the calcification process continues, spicules of bone will radiate 
from the center of ossification and will become surrounded by compact mesenchymal 
cells that will form the periosteum (membrane surrounding the bone).  The 
mesenchymal cells lining the periosteum will differentiate into osteoblasts that will 
deposit osteoid matrix parallel to the existing spicules, creating one of the many layers 
of bone.6		
Figure 1.1 Steps of Intramembranous Ossification 
 
1.3 Proteins and Genes Involved in Osteogenesis 
Bone tissue is composed of cells (osteoblasts and osteoclasts) and a matrix. Ninety 
percent of the bone matrix contains type I collagen with the other ten percent composing 
a large number of noncollagenous proteins such as osteocalcin, osteonectin, bone 
sialoproteins, and proteoglycans. These non-collagenous proteins participate in matrix 
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maturation, mineralization and perhaps the regulation of the activity of bone cells. 
Hormones, growth factors, mechanical stimuli, and cell to cell and cell to matrix 
interactions, act by signaling pathways to activate transcription factors that effect the 
expression of genes, thereby regulating osteoblast differentiation and commitment.7  
 
Intramembranous ossification involves bone morphogenic proteins and the activation of 
transcription factor Cbfa1 (RunX2). It is believed that bone morphogenic proteins 
activate the Cbfa1 gene in neural crest derived mesenchymal cells to transform them 









Figure 1.2 Influence of BMP and RunX2 on Osteoblast Differentiation 
 
Studies have found that the mRNA for Cbfa1 in mice is restricted to the mesenchyme 
that forms bone and is limited to the lineage of osteoblasts. This protein activates genes 
for osteopontin, osteocalcin, bone sialoprotein, alkaline phosphatase, collagen type I and 









Figure 1.3 Gene Activation by RunX2 
 
1.4  Phenotypic Characteristics During Osteogenic Differentiation of Mesenchymal    
Stem Cells 
 Osteoblasts (bone forming cells) are differentiated from precursor cells present within 
the bone marrow stroma (non-hematopoietic compartment of bone marrow). These 
fibroblast-like stem cells with osteogenic differentiation potential are referred to as 
mesenchymal stem cells.7 Mesenchymal stem cells (MSCs) are multipotent∗ adult stem 
cells with the capability of differentiating into various tissue types, including bone. 
During osteogenic differentiation of MSCs, there are many changes in gene expression, 
most importantly the up-regulation of osteopontin, osteocalcin, alkaline phosphatase, 
collagen type I and core binding factor α1. When expressed, these markers are indicative 
of osteogenic differentiation with their level of expression being equivocal to the stage 
of differentiation.9   
 
																																																								
∗ Multipotent Stem Cell- Cells that can differentiate into a number of cells from a germ layer.9 
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There are three distinct phases of osteogenic differentiation: Proliferation, Extracellular 
matrix maturation and Matrix mineralization.9 During days one to four, the proliferative 
stage takes place, where the MSCs are highly mitotic creating a peak in the number of 
cells.9,10 At this phase, there is a high expression of H4 histone and c-fos as well as a 
peak level of genes associated with extracellular matrix production, such as collagen 
type I, fibronectin and transforming growth factor β.9 This stage is followed by early cell 
differentiation, days 5-14, where alkaline phosphatase activity will be at maximal level. 
Also found at this stage is the expression of collagen type I matrix, onto which the 
mineral is deposited. With the final stage, days 14- 28, there is an increased expression 
of osteocalcin and osteopontin, followed by the deposition of phosphate and calcium.10 
 
Alkaline phosphatase expression is low as osteoprogenitor cells undergo proliferation. 
Its activity rises during differentiation and maturation, followed by a decline and 
absence as osteoblasts turn into osteocytes. Alkaline phosphatase activity generally takes 
place prior to osteocalcin, implying that it is an early osteoblast marker, while 
osteocalcin indicates a more mature phenotype as seen with osteocytes. Their expression 
has been used as identifying markers for osteoblasts. Another marker for osteogenic 
differentiation is osteopontin, which is expressed during the early stages of osteogenesis 
prior to mineralization or osteocalcin expression (Figure 1.4). Therefore, this marker is 










Figure 1.4 Phenotypic Characteristics During Osteogenic Differentiation of 
Mesenchymal Stem Cells  
 
1.5  Therapuetic Application of Mesenchymal Stem Cells 
Mesenchymal stem cells have become an important field of study for tissue regeneration 
and regenerative medicine.11 They have illustrated the ability to differentiate into several 
types of cells including, osteocytes, chondrocytes, neurons, and cardiomyoctes, making 
them a promising resource for regenerative cell therapy for various diseases.12 Although 
most mesenchymal stem cells are derived from bone marrow, a study by Tomar et al. 
has demonstrated that mesenchymal stem cells derived from human gingiva are far more 
superior. These cells are easy to isolate, are uniformly homogenous, proliferate faster, 
are not tumorigenic, display stable phenotype, and maintain normal karyotype and 




1.6 Osteogenic Differentiation Role of Dexamethasone 
Several in vitro studies have been conducted utilizing a mixture of dexamethasone, 
calcitriol, ascorbic acid, and β-glycerophosphate to demonstrate the differentiation of 
bone marrow derived mesenchymal cells into osteoblasts. This differentiation has been 
confirmed by illustrating the induction of osteoblast specific gene expression and 
proteins.7  
 
Dexamethasone supports osteogenic differentiation by binding to regulatory proteins 
and activating transcription of osteoblast specific genes within cells. Evidence has also 
shown that dexamethasone functions at multiple points of the osteoblastic differentiation 
process. In vitro, constant treatment with the corticosteroid would increase alkaline 
phosphatase activity, which is necessary for matrix mineralization and morphological 
changes of mesenchymal stem cells. Constant presence of dexamethasone in the culture 
medium is required to achieve maximal osteoblastic differentiation of mesenchymal 
cells, however, a prolonged presence in differentiation media would have toxic effects 
on osteoblasts and cause lysis of cells.9 
 
1.7 Osteogenic Differentiation Role of Antioxidants 
Studies have shown that antioxidants play a vital role in stem cell proliferation and 
differentiation.14,15 Curcumin, a natural phenol derived from Curcuma longa (turmeric), 
has been shown to exhibit anti-inflammatory, anti-mutagenic, and anti-carcinogenic 
properties. It can inhibit osteoclastogenesis, induce apoptosis in osteoclasts, and can 
directly interact with adiopocytes to suppress their differentiation.16-18 A study 
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conducted by Gu et al., demonstrated that curcumin can promote osteogenic 
differentiation of rat derived bone marrow mesenchymal cells, suggesting that curcumin 
can be used in the treatment of bone defects.19 Bromelain, a known antioxidant derived 
from pineapple extract, has also demonstrated anti-inflammatory and analgesic 
properties.  Bromelain has also shown to have the ability to inhibit adipocyte 
differentiation by reducing adipogenic gene expression and to induce apoptosis and 
lipolysis in mature adipocytes. Furthermore, its wound healing ability and tissue 
regenerating capability indicate that bromelain may assist in the bone tissue repair 
process and promote tissue regeneration.20-22 
 
1.8 Objective 
The aim of this study was to investigate the effects of curcumin and bromelain on 
osteogenic differentiation of human gingiva derived mesenchymal stem cells 
(HGMSCs) and to compare their differentiation potential to dexamethasone. 
 
1.9 Long Term Goal 
Due to the limitation of bone grafting procedures on the treatment of bone defects, an 
alternative approach to treatment is necessary. The long-term goal of this study is to 
repair craniofacial defects using cell based tissue engineering techniques. Tissue 
engineering involves the implantation of a synthetic scaffold seeded with mesenchymal 
stem cells and molecular signals at the bone defect site. Harvesting cells from bone 
marrow is the classical approach to this technique, but is invasive. The need for a more 
available source of mesenchymal stem cells has lead to the investigation of other 
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tissues.7 Human gingiva derived tissue is a readily accessible source of neural crest 
derived MSC and can be easily isolated making them an ideal source for cell therapy in 
regenerative medicine.13 Furthermore, their low toxicity, anti-inflammatory property, 
wound healing ability, and capability to influence the differentiation of mesenchymal 
stem cells, indicate that antioxidants (bromelain and curcumin) may assist in bone tissue 
repair and promote tissue regeneration in individuals with craniofacial defects.16-22 
 
1.10 Innovation 
To the best of our knowledge, this was the first study to determine the effects of 
antioxidants (bromelain and curcumin) on the osteogenic differentiation of human 














CHAPTER 2. MATERIALS AND METHODS 
2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), Fetal Bovine Serum (FBS), Phosphate 
Buffered Saline (PBS), Penicillin/Streptomycin, Von Kossa Stain, Alizarin Red Stain, 
Ascorbic Acid, β-glycerophosphate, Dexamethasone, Dimethyl Sulfoxide (DMSO), 
Collagenase, Dispase, L-glutamine, Curcumin, and Bromelain were purchased from 
Sigma Aldrich (St. Louis, MO). Trypsin, Gene Expression Assay Mix and cDNA kit 
were purchased from Life Technology (Carlsbad, CA). MTT reagent and Alkaline 
Phosphate Assay kit was purchased from Sciencell (Carlsbad, CA). The Mesenchymal 
Stem Cell Phenotyping kit, Human was purchased from Miltenyi Biotec (Auburn, CA). 
Tissue culture flasks, micropipettes, tissue culture plates and other lab supplies were 
obtained from VWR International Company (Atlanta, GA). 
 
2.2 Overall Study Design 
Human gingival tissue samples from three healthy individuals were collected under the 
approved IRB protocol at NSU College of Dental Medicine. Stem cells were isolated 
and incubated under standard culture conditions for expansion until confluency was 
reached. Cells were then cryopreserved. Cryopreserved human gingival stem cells 
(HGMSCs) were all revived at the same time and maintained under standard expansion 
culture conditions until confluent. Mesenchymal surface markers were detected via Flow 
Cytometry. Cells were induced with osteogenic medium (DMEM, 10% FBS, 1% 
antibiotic/antimycotic solution, 10Mm β-glycerophosphate, and 50µg/mL ascorbic acid) 
supplemented with 100nM Dexamethasone	and monitored at 1,2,3, and 4 week intervals 
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to determine their osteogenic potential. At day 21, cells were stained with Alizarin Red 
S and Von Kossa to examine the presence of mineralization.  To test the effect of 
bromelain and curcumin on cell proliferation, cells were treated with either antioxidant 
at different concentrations and incubated for 1,3, and 5 days. Cells cultured in complete 
medium (DMEM, 10% FBS, 1% antibiotic/antimycotic solution) were used as control. 
At each time point, cells were analyzed for proliferation. For gene expression analysis, 
cells cultured in OM (DMEM, 10% FBS, antibiotic/antimycotic solution, β-
glycerophosphate, and ascorbic acid) were designated as the control group. 
Experimental groups included cells cultured in OM + DEX as well as cells cultured in 
OM with their assigned concentration of either bromelain or curcumin as found in Table 
2.2 After two weeks of treatment, cells were harvested and RNA was extracted using 
Trizol method.  cDNA was then prepared via the reverse transcription method. Gene 
expression analysis of selected osteogenic markers (ALP, OPN, OPG, ONN, Collagen) 












Figure 2.1 Overall Study Design 
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2.3 Sample Size Determination 
Cells from three donors were randomly selected for this study. For the study of cell 
proliferation, there was 1 control group and 12 experimental groups (6 Curcumin and 6 
Bromelain).  The control group consisted of cells cultured in a complete medium 
(DMEM, 10% FBS, 1% antibiotic/antimycotic solution) and the experimental group 
cells were cultured in a complete medium with an assigned antioxidant dose as found in 
Table 2.1.  The cells were treated at day intervals of 1,3,5 and analyzed for cell viability 
and proliferation via the MTT Assay. The sample size was calculated as follows: 3 
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donors x 1 control group x 12 experimental groups (6 Curcumin and 6 Bromelain) x 3 
treatment days = 108 samples. 
 
For the study of gene expression, there were 2 control groups, 2 dexamethasone groups 
and 6 experimental groups (3 Bromelain and 3 Curcumin).  The control groups consisted 
of cells cultured in an osteogenic medium (DMEM, 10% FBS, antibiotic/antimycotic 
solution, β-glycerophosphate, and ascorbic acid), the dexamethasone groups consisted of 
cells cultures in an osteogenic medium supplemented with 100nM dexamethasone and 
the experimental group cells were cultured in an osteogenic medium with an assigned 
antioxidant dose as found in Table 2.2.  The cells were treated for two weeks and 
analyzed for osteogenic differentiation via PCR. The sample size was calculated as 
follows: 3 donors x 2 control groups x 2 dexamethasone groups x 6 experimental groups 
(3 Curcumin and 3 Bromelain) x 1 treatment day = 72 samples.  Overall, sample size 
was 72, which includes three biological replicas and for each biological replica two 
technical replicas have been used.  
 
2.4 Methodology 
Under the approved Institutional Review Board protocol (#2018-241), samples of 
gingival tissue were obtained from discarded or remnant tissues from three random 
healthy individuals who were undergoing procedures at Nova Southeastern University 
College of Dental Medicine. Mesenchymal stem cells were isolated from these tissues 
using established methods from previous studies.13,23 The tissues were de-epithelialized 
and washed in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
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Fetal Bovine Serum (FBS), 400 mmol/ml L-glutamine, 100 1g/ml streptomycin, 1% 
amphotericin, and 100 U/ml penicillin. Tissues were then minced, placed in a medium 
containing 0.1% collagenase and 0.2% dispase and incubated at 37°C for 15 minutes.  
Tissues were again treated with 0.1% collagenase and 0.2% dispase and incubated at 
37°C for 5, 10 and 15 minute increments and cell suspensions were pooled. The pooled 
cell suspension was centrifuged and the pellet was re-suspended in DMEM 
supplemented with 10% FBS and seeded (1x2x104 cells cm2) in a tissue culture flask. 
Plated cells were expanded in a medium containing DMEM supplemented with 10% 
FBS, and 100 U/ml penicillin/100µg/ml streptomycin and cultured at 37°C in a 
humidified tissue culture incubator with 5% CO2 and 95% O2. After 48 hours, non-
adherent cells were removed. Remaining cells were fed with culture medium every 2-3 
days until 70-80% confluency was reached, then cryopreserved.  
 
2.5 Cell Culture 
Cryopreserved cells were revived and re-suspended in DMEM containing 10% FBS and 
seeded (2x104 cells cm2) in a tissue culture flask. The cells plated in the culture flask 
were then expanded in a medium containing DMEM, 10% FBS, and 1% 
antibiotic/antimycotic solution at 37°C and 5% CO2 and 95% O2 for 48 hours. After 48 
hours, non-adherent cells were removed and the medium was changed. Cells were 
continuously sub-cultured and maintained in culture medium. Cells from fourth and fifth 




2.6 Cell Surface Marker Detection via Flow Cytometry 
Utilizing the Human Mesenchymal Stem Cell Phenotyping kit, samples of cells at the 
concentration of 1x106 were used for the detection of mesenchymal stem cell surface 
markers via flow cytometric analysis. Samples were prepared according to manufacturer 
protocol. Positive markers include: CD90, CD73, CD105 and negative markers include: 
CD45, CD34, CD11b, CD79A, and HLA-DR as determined by the criteria set forth by 
the International Society for Cellular Therapy.24 Fluorescence intensity of the cell 
samples was evaluated using the FACScan flow cytometer (BD Biosciences; San Jose, 
CA) at the University of Miami. Data analysis was completed using CellQuest Software 
(BD Biosciences; San Jose, CA). 
 
2.7 In-Vitro Osteoblast Differentiation Assays 
Mesenchymal stem cells were incubated either in CM (DMEM, 10% FBS, 1% 
antibiotic/antimycotic solution) or CM supplemented with 10% FBS, 10mM β-
glycerophosphate, 50µg/mL ascorbic acid, and 100nM dexamethasone. Cell cultures 
were fed every 2-3 days and characterized after 21-25 days by Alizarin Red S and Von 
Kossa staining. 
 
2.7.1 Mineralization Assay: Alizarin Red S Stain 
At the end of the third and fourth week of treatment, cells were washed three times with 
PBS and fixed in 10% formalin for 10 minutes at room temperature. Cells were rinsed 
twice with distilled water and incubated in 1% Alizarin Red solution (Spectrum) for 10 
minutes, followed by a gentle wash with distilled water.  
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2.7.2 Mineralization Assay: Von Kossa Stain 
At the end of both treatment weeks (week three and four), cells were washed three times 
with PBS and fixed in 10% formalin for 10 minutes at room temperature. Cells were 
rinsed twice with distilled water and incubated in 2% silver nitrate and exposed to UV 
light for 1 hour. The silver nitrate solution was then removed and cells were rinsed with 
distilled water three times, exposed to bright light for 15 minutes, and dehydrated in 
100% ethanol.  
 
2.8 Cell Proliferation Study  
HGMSCs grown to 80-90% confluency were then trypsinized and plated into a 96 well 
plate at 10,000 cells/well.  Cells were assigned into treatment groups as illustrated in 
Table 2.1. Cells were incubated at 37°C and 5% CO2 and 95% O2 for 24 hours, then 
further incubated for 1,3, or 5 days within their assigned culture media (CM, Bromelain 
or Curcumin). Cells incubated in CM alone were considered the control group. Cells 
were then analyzed for proliferation via the MTT assay (a colorimetric assay). The MTT 
assay was completed for each group at each day interval following manufacturer 
protocol. Each well of cells received 10µL of MTT reagent ((3-(4,5-dimethylthiazol-2-
yl)-2,5 diphenyltetrazolium bromide) and were incubated at 37°C for 4 hours. A 
negative control of 10µL MTT reagent was added to 100µL of complete medium alone. 
50µL of dimethyl sulfoxide (DMSO) was then added to each well and mixed. Cells were 
again incubated at 37°C for 10 minutes. Absorbance was read at 540nm. A reduction in 
















Figure 2.2 Depiction of the MTT Assay Procedure 
 
 
2.9 Gene Expression Study 
 
HGMSCs grown to 80-90% confluency were then further cultured in an assigned media, 
as found in Table 2.2, and were treated for 2 weeks at 37°C and 5% CO2 and 95% O2.  
Cells treated with complete medium supplemented with ascorbic acid and  
β-glycerophosphate was assigned as the control (OM) and cells treated with either 
dexamethasone (DEX), curcumin, or bromelain were designated as experimental groups.  
After two weeks of treatment, cells were harvested and RNA was extracted using the 
TRIzol method per manufacturer protocol. cDNA was then prepared via reverse 
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transcriptase following manufacturer guidelines. Gene expression analysis of selected 
osteogenic markers (Alkaline phosphatase, Collagen type I, Osteonectin, Osteopontin 
and Osteoprotegerin) was then measured by PCR and gel electrophoresis to determine 
cell differentiation and osteogenic differentiation (Figure 2.3). 
 
 
Figure 2.3 Depiction of Gene Expression Studies 
 
2.10 Statistical Analysis 
Data was analyzed usind the repeated measures of one way analysis of variance 







CHAPTER 3. RESULTS 
3.1 Cell Morphology 
Cells were seeded (0.5x106 cells cm2) and cultured in a medium containing DMEM 
supplemented with 10% FBS and 100 U/ml penicillin/100µg/ml streptomycin at 37°C 
with 5% CO2 and 95% O2 (Figure 3.1A).  Cells reached 80-90% confluency at one week 
after seeding (Figure 3.1D).  Images depict a homogenous cell population of spindle 
shaped cells (Figure 3.1B, 3.1C, and 3.1D).	 
 
Figure 3.1 Morphologic Images of HGMSCs. Phase contrast micrographs at Day 0 (A), 





3.2 Flow Cytometry Analysis 
Cell surface markers were examined to confirm that they exhibit the characteristic 
features found in mesenchymal stem cells. Results revealed that the cells were positive 
for mesenchymal stem cell markers CD73, CD90, CD105 and were negative for 
hematopoietic stem cell markers CD34, CD14, CD45, and CD20 (Figure 3.2). 
Figure 3.2 Flow Cytometric Analysis of HGMSCs. 
Cells were more than 90% positive for the expression of cell surface markers related to 
those found in mesenchymal stem cells (CD105, CD90 and CD73) and negative for 






3.3 In vitro Mineralization 
The osteogenic differentiation potential of human gingiva derived mesenchymal stem 
cells was determined by culturing cells in osteogenic induction medium for 4 weeks. At 
the end of week 4, they were examined for mineral nodule formation. Results revealed 
that cells induced with osteogenic supplements were positive for mineral aggregates and 
calcification by Alizarin Red S and Von Kossa stain (Figure 3.3B, 3.3D).  
Figure 3.3 Osteogenic Differentiation Potential of Gingiva Derived Mesenchymal Stem 
Cells. Alizarin Red S stain negative to cells cultured in complete medium (A) and 
positive to cells cultured in osteogenic medium (B).  Von Kossa stain negative to cells 










3.4 Effects of Bromelain and Curcumin on Cell Proliferation  
 
Cells were treated as described in the methodology section 2.8. On day 1, cells induced 
with bromelain showed increased proliferation at 1µg/ml concentration.  At all other 
concentrations, cell proliferation was comparable to those untreated with the antioxidant. 
On day 3, bromelain treatment enhanced human gingival mesenchymal stem cell 
proliferation at all concentrations. On day 5, there was a gradual decrease in cell 
proliferation with increasing concentrations of bromelain. Bromelain did not inhibit 
HGMSCs survival at any concentration (Figure 3.4).  
 
In the presence of curcumin, cells displayed higher proliferation rates at wide 
concentration ranges (0.5-5µM) with a significant decrease at 15µM on day 1. Curcumin 
exhibited a dose dependent proliferation on day 3. On day 5, curcumin inhibited cell 
growth at higher concentrations (10-15µM), while lower concentrations did not affect 
































Figure 3.4 Effect of Bromelain Treatment on the Proliferation of HGMSCs. Cells were 
incubated with or without various concentrations of bromelain for 1,3, or 5 days. The 

















Figure 3.5 Effect of Curcumin Treatment on the Proliferation of HGMSCs. Cells were 
incubated with or without various concentrations of curcumin for 1, 3, or 5 days. The CM 
















































3.5 Effects of Bromelain and Curcumin on Gene Expression 
ALP, OPG, ONN and Collagen Type I gene expression was examined by PCR after 
HGMSCs were cultured in OM, DEX or different concentrations of bromelain or 
curcumin (as noted in Table 2.2) for two weeks (Figures 3.6, 3.7, 3.8, and 3.9). After 14 
days of treatment, ALP (p<0.01), OPG (p=0.04), and ONN  (p<0.01) were significantly 
up-regulated by bromelain and curcumin treatment in a dose-dependent manner. While 
DEX treatment induced the up-regulation of genes ALP, OPG, ONN after 14 days of 
treatment, collagen type I was comparable with the control (OM). As illustrated in 
Figure 3.6, the bromelain-treated groups exhibited significantly greater expression of 
ALP (p<0.001) and OPG (p<0.05) than cells treated with OM. While the bromelain 
treated group showed enhanced expression of ALP and OPG, the increase was not 
significantly higher than the DEX treated groups. Both OPG and ONN significantly 
increased at 5µg/ml (Figure 3.6 and 3.7). As depicted in Figure 3.8, ALP was 
significantly expressed with lower concentrations of curcumin. ONN expressed at the 
highest concentration of 10µM (Figure 3.9). Both bromelain and curcumin did not effect 









                                                                                                                                     





                                                                                                                             
 
















Figure 3.9 The Expression of ONN and Collagen Type I in HGMSCs Cultured in OM, 





3.6 Osteogenic Marker Genes 
Osteogenic marker genes were investigated via RT-PCR to confirm the osteogenic 
differentiation of human gingival mesenchymal stem cells when grown in media treated 
with dexamethasone, curcumin or bromelain. Results demonstrated that curcumin and 
bromelain induced osteogenic differentiation in a dose dependent manner. At 2.5µg the 
peak up-regulation could be seen for genes Col Type I, ALP, and OPG for bromelain 
treated cells (Figure 3.10). In curcumin, the maximum enhancement has been observed 














Figure 3.10 Identification of Osteogenic Marker Genes in HGMSCs Treated with 
Bromelain. Osteogenic differentiation of HGMSCs was determined by investing the 
osteogenic marker genes ALP, Col Type I, ONN, and OPG by RT-PCR. B-actin was 
used as an endogenous control. CM and OM were considered control media. At 2.5µg, 











Figure 3.11 Identification of Osteogenic Marker Genes in HGMSCs Treated with 
Curcumin. Osteogenic differentiation of HGMSCs was determined by investing the 
osteogenic marker genes ALP, Col Type I, OPN, and ONN by RT-PCR. B-actin was 
used as an endogenous control. CM and OM were considered control media. At 2µM, 




















CHAPTER 4. DISCUSSION 
Due to their highly proliferative capacity and multilineage differentiation potential, 
mesenchymal stem cells have become an attractive candidate for clinical application.9,25 
Most cell based therapies were conducted using mesenchymal stem cells derived from 
bone marrow, however, their limitation of availability and difficulty of harvesting large 
volumes have led to the investigation of other tissue sources.13,23 In 2010, Zhang et al. 
isolated mesenchymal stem cells from human gingiva and characterized them as having 
the ability to differentiate into multi-lineages. Tomar et al. has demonstrated that 
mesenchymal stem cells derived from human gingiva are far more superior to those 
derived from bone marrow.13 A study conducted by Xu et al. has demonstrated that 90% 
of the mesenchymal stem cells isolated from gingiva are derived from cranial neural 
crest cells and exhibit the same multipotency.26 Based on these findings, HGMSCs may 
be an ideal cell source for repairing craniofacial defects.  
 
The in vitro differentiation of mesenchymal stem cells depends upon the conditions in 
which they are cultured. Typical in vitro osteogenic differentiation media contains 
ascorbic acid, dexamethasone, and β-glycerophosphate.9,10 A constant presence of 
dexamethasone in culture medium is necessary to achieve complete differentiation of 
mesenchymal stem cells into osteoblasts. Although long-term exposure of 
dexamethasone enhances in vitro differentiation of MSCs (bone formation), its effects in 
vivo are contradictory and can lead to bone degeneration and loss.9 Antioxidants play a 
vital role in stem cell proliferation and differentiation, therefore, may provide an 
alternative to dexamethasone in osteogenic media 14,15 The present study was focused on 
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investigating the effects of curcumin and bromelain on osteogenic differentiation of 
human gingiva derived mesenchymal stem cells (HGMSCs) and to compare their 
differentiation potential to dexamethasone. 
 
In this study, the addition of bromelain to the culture medium enhanced cell proliferation 
at lower concentrations (1µg/ml-5µg/ml). Cells exposed to bromelain for 24 hours 
showed a high proliferation rate at 1µg/ml. On day 3, an increase in proliferation was 
observed with all concentrations. There was a gradual decrease in higher concentrations 
of bromelain on day 5. Overall, results demonstrated that bromelain did not inhibit the 
survival of HGMSCs at any concentration. Amini et al., Dave et al., and Grabowska et 
al., reported that bromelain inhibited cell proliferation in a concentration dependent 
manner. In all studies, cell viability was significantly reduced when exposed to higher 
concentrations of bromelain.21,27,28 Amini et al., exposed experimental cells to bromelain 
concentrations ranging from 5µg/ml-600µg/ml. Their results showed a concentration 
dependent cell inhibitory effect with half maximal inhibitory values ranging from 
29µg/ml-142µg/ml.28 Our pilot studies revealed that concentrations over 15µg/ml were 
causing apoptosis in HGMSCs exposed to bromelain for 72 hours. Based on these 
results, further experiments were conducted with a concentration range of 1µg/ml-
15µg/ml.   
 
In the presence of curcumin, our data exhibited higher proliferation rates of HGMSCs at 
wide concentration ranges (0.5µg/M-5µg/M). Cells displayed higher proliferation rates 
at lower concentrations (0.5µg/M-5µg/M) with a significant decrease at 15µg/M on  
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day 1. Curcumin exhibited a dose dependent proliferation on day 3.  A similar effect was 
found in the study conducted by Moran et al., who showed that the treatment of human 
osteoblast–like cells with curcumin inhibited their proliferation in a dose dependent 
manner.29 On day 5, curcumin inhibited cell growth at higher concentrations (10µg/M-
15µg/M). Overall, the proliferation of HGMSCs was significantly higher when the cells 
were exposed to curcumin at lower concentrations (0.5µg/M-5µg/M), while higher 
concentrations 10µg/M and 15µg/M caused cytotoxicity after prolonged period of 
exposure. Kim et al. revealed similar findings, which found that lower concentrations of 
curcumin can induce the proliferation of mouse multi-potent neural progenitor cells, 
while high doses of curcumin are cytotoxic.30 
 
Our study demonstrated that the treatment of curcumin and bromelain significantly     
up-regulated the osteogenic gene expression of ALP, OPG, ONN and Collagen Type I  
in HGMSCs. These findings are supported by the study conducted by Son et al., where 
curcumin increased the expression of genes such as RunX2, ALP, and OC (osteocalcin), 
which consequently induced the differentiation of mouse embryonic stem cells into 
osteoblasts.31 With curcumin treatment, gene expression patterns were not concentration 
dependent, suggesting that curcumin is an effective inducer of osteoblast differentiation 
at all concentrations in this study. However, cells were never exposed to a concentration 
more than 10ug/ml due to the fact that it caused apoptosis at higher concentrations, as 
evident in previous studies. The bromelain treated groups exhibited significantly greater 
expression of ALP than cells treated with DEX. To our knowledge, this is the first 
evaluation of bromelain as an inducer of osteoblast differentiation. Since a similar 
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osteogenic induction was also seen in the DEX treated groups, the results from our the 
study suggests that curcumin or bromelain can be used as substitute of DEX.   
 
In conclusion, curcumin and bromelain treatment may help establish an environment 
that facilitates osteodifferentiation of mesenchymal stem cells in vivo. This strategy may 


















































1. Merritt L. Part 2. Physical assessment of the infant with cleft lip and/or palate. 
Advances in neonatal care : official journal of the National Association of 
Neonatal Nurses. 2005;5(3):125-134. 
2. Cleft lip and palate. ClinicalKey: Elsevier; 2012. 
3. Merritt L. Part 1. Understanding the embryology and genetics of cleft lip and 
palate. Advances in neonatal care : official journal of the National Association of 
Neonatal Nurses. 2005;5(2):64-71. 
4. Bender PL. Genetics of cleft lip and palate. Journal of Pediatric Nursing. 
2000;15(4):242-249. 
5. http://staff.aub.edu.lb/~weborthod/downloads/courses/ODO.12-1.pdf. 
6. Gilbert F. Development Biology. Osteogenesis: The Development of Bones. Vol 
6 edition. Sunderlant (MA): Sinauer Associates; 2000. 
7. Arvidson K, Abdallah BM, Applegate LA, et al. Bone regeneration and stem 
cells. Journal of cellular and molecular medicine. 2011;15(4):718-746. 
8. Cartmell GRKaSH. Topics in Tissue Engineering. In: N. Ashammakhi RLR, E. 
Chiellini, ed. Genes and Proteins Involved in the Regulation of Osteogenesis. 
Vol 32007. 
9. Kamran Kaveh RI, Md. Zuki Abu Bakar and Tengku Azmi Ibrahim. 
Mesenchymal Stem Cells, Osteogenic Lineage and Bone Tissue Engineering: A 
Review. Journal of Animal and Veterinary Advances. 2011;10(17):2317-2330. 
10. Birmingham E, Niebur GL, McHugh PE, Shaw G, Barry FP, McNamara LM. 
Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte 
and osteoblast cells in a simplified bone niche. European cells & materials. 
2012;23:13-27. 
11. Huang GT, Gronthos S, Shi S. Mesenchymal stem cells derived from dental 
tissues vs. those from other sources: their biology and role in regenerative 
medicine. Journal of dental research. 2009;88(9):792-806. 
12. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult 
human mesenchymal stem cells. Science (New York, NY). 1999;284(5411):143-
147. 
13. Tomar GB, Srivastava RK, Gupta N, et al. Human gingiva-derived mesenchymal 
stem cells are superior to bone marrow-derived mesenchymal stem cells for cell 
therapy in regenerative medicine. Biochemical and biophysical research 
communications. 2010;393(3):377-383. 
14. Mekala NK, Baadhe RR, Rao Parcha S, Prameela Devi Y. Enhanced 
proliferation and osteogenic differentiation of human umbilical cord blood stem 
cells by L-ascorbic acid, in vitro. Current stem cell research & therapy. 
2013;8(2):156-162. 
15. Sun LY, Pang CY, Li DK, et al. Antioxidants cause rapid expansion of human 
adipose-derived mesenchymal stem cells via CDK and CDK inhibitor regulation. 




16. Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (Curcuma 
longa) inhibits inflammatory nuclear factor (NF)-kappaB and NF-kappaB-
regulated gene products and induces death receptors leading to suppressed 
proliferation, induced chemosensitization, and suppressed osteoclastogenesis. 
Molecular nutrition & food research. 2012;56(3):454-465. 
17. Oh S, Kyung TW, Choi HS. Curcumin inhibits osteoclastogenesis by decreasing 
receptor activator of nuclear factor-kappaB ligand (RANKL) in bone marrow 
stromal cells. Molecules and cells. 2008;26(5):486-489. 
18. Bharti AC, Takada Y, Aggarwal BB. Curcumin (diferuloylmethane) inhibits 
receptor activator of NF-kappa B ligand-induced NF-kappa B activation in 
osteoclast precursors and suppresses osteoclastogenesis. Journal of immunology 
(Baltimore, Md : 1950). 2004;172(10):5940-5947. 
19. Gu Q, Cai Y, Huang C, Shi Q, Yang H. Curcumin increases rat mesenchymal 
stem cell osteoblast differentiation but inhibits adipocyte differentiation. 
Pharmacognosy magazine. 2012;8(31):202-208. 
20. Brien S, Lewith G, Walker A, Hicks SM, Middleton D. Bromelain as a 
Treatment for Osteoarthritis: a Review of Clinical Studies. Evidence-based 
complementary and alternative medicine : eCAM. 2004;1(3):251-257. 
21. Dave S, Kaur NJ, Nanduri R, Dkhar HK, Kumar A, Gupta P. Inhibition of 
adipogenesis and induction of apoptosis and lipolysis by stem bromelain in 3T3-
L1 adipocytes. PloS one. 2012;7(1):e30831. 
22. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cellular 
and molecular life sciences : CMLS. 2001;58(9):1234-1245. 
23. Zhang Q, Shi S, Liu Y, et al. Mesenchymal stem cells derived from human 
gingiva are capable of immunomodulatory functions and ameliorate 
inflammation-related tissue destruction in experimental colitis. Journal of 
immunology (Baltimore, Md : 1950). 2009;183(12):7787-7798. 
24. Human Mesenchymal Stem Cell Verification Flow Kit Protocol, R &D Systems. 
25. Patel DM, Shah J, Srivastava AS. Therapeutic potential of mesenchymal stem 
cells in regenerative medicine. Stem cells international. 2013;2013:496218. 
26. Xu X, Chen C, Akiyama K, et al. Gingivae contain neural-crest- and mesoderm-
derived mesenchymal stem cells. Journal of dental research. 2013;92(9):825-
832. 
27. Grabowska E, Eckert K, Fichtner I, Schulzeforster K, Maurer H. Bromelain 
proteases suppress growth, invasion and lung metastasis of B16F10 mouse 
melanoma cells. International journal of oncology. 1997;11(2):243-248. 
28. Amini A, Ehteda A, Masoumi Moghaddam S, Akhter J, Pillai K, Morris DL. 
Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines 
(MKN45, KATO-III, HT29-5F12, and HT29-5M21). OncoTargets and therapy. 
2013;6:403-409. 
29. Moran JM, Roncero-Martin R, Rodriguez-Velasco FJ, et al. Effects of curcumin 
on the proliferation and mineralization of human osteoblast-like cells: 
implications of nitric oxide. International journal of molecular sciences. 
2012;13(12):16104-16118. 
	 41	
30. Kim SJ, Son TG, Park HR, et al. Curcumin stimulates proliferation of embryonic 
neural progenitor cells and neurogenesis in the adult hippocampus. The Journal 
of biological chemistry. 2008;283(21):14497-14505. 
31. Son HE, Kim EJ, Jang WG. Curcumin induces osteoblast differentiation through 
mild-endoplasmic reticulum stress-mediated such as BMP2 on osteoblast cells. 
Life sciences. 2018;193:34-39. 
 
